Compare ACHV & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACHV | XFLT |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.2M | 255.1M |
| IPO Year | 2018 | N/A |
| Metric | ACHV | XFLT |
|---|---|---|
| Price | $2.89 | $17.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 615.8K | ★ 794.5K |
| Earning Date | 03-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $578.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $3.02 |
| 52 Week High | $6.03 | $16.38 |
| Indicator | ACHV | XFLT |
|---|---|---|
| Relative Strength Index (RSI) | 24.33 | 95.49 |
| Support Level | $2.38 | $5.00 |
| Resistance Level | $3.39 | N/A |
| Average True Range (ATR) | 0.25 | 0.24 |
| MACD | -0.15 | 1.66 |
| Stochastic Oscillator | 11.27 | 99.75 |
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.